A systematic review of the effectiveness of adalimumab
A systematic review of the effectiveness of adalimumab
A systematic review of the effectiveness of adalimumab
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
44<br />
Effectiveness<br />
Review: Etanercept for rheumatoid arthritis 2006<br />
Comparison: 03 Etanercept s.c. licensed dose only (25 mg twice weekly) vs o<strong>the</strong>r active treatment<br />
Outcome: 12 HAQ, end <strong>of</strong> study result<br />
Study<br />
or subcategory<br />
N<br />
Etanercept<br />
mean (SD) N<br />
Control<br />
mean (SD)<br />
01 Partial responders to comparator DMARD (SSZ)<br />
Codreanu, 2003103 [24 weeks] 103 1.10 (0.60) 50 1.50 (0.50)<br />
Subtotal (95% CI)<br />
Test for heterogeneity: NA<br />
103 50<br />
Test for overall effect: z = 4.34 (p < 0.0001)<br />
02 Responders or naive to comparator DMARD (MTX)<br />
TEMPO 110 [100 weeks]<br />
ERA 124 [104 weeks]<br />
Subtotal (95% CI)<br />
223 1.00 (0.70) 228 1.10 (0.70)<br />
207 0.70 (0.70) 217 0.80 (0.70)<br />
430 445<br />
Test for heterogeneity: 2 = 8.59E-32, df = 1 (p = 1.00), I 2 = 0%<br />
Test for overall effect: z = 2.11 (p = 0.03)<br />
Total (95% CI)<br />
Test for heterogeneity: 2 = 8.38, df = 2 (p = 0.02), I2 533 495<br />
= 76.1%<br />
Test for overall effect: z = 3.86 (p = 0.0001)<br />
FIGURE 19 HAQ change: etanercept licensed dose versus o<strong>the</strong>r active treatment<br />
Review: Etanercept for rheumatoid arthritis 2006<br />
Comparison: 03 Etanercept s.c. licensed dose only (25 mg twice weekly) vs o<strong>the</strong>r active treatment<br />
Outcome: 07 SAEs<br />
Study<br />
or subcategory<br />
01 Partial responders to comparator DMARD (SSZ)<br />
Codreanu, 2003 103 [24 weeks]<br />
Subtotal (95% CI)<br />
Total events: 5 (etanercept), 1 (control)<br />
Test for heterogeneity: NA<br />
Test for overall effect: z = 0.82 (p = 0.41)<br />
02 Responders or naive to comparator DMARD (MTX)<br />
TEMPO 110 [104 weeks]<br />
Subtotal (95% CI)<br />
Total events: 44 (etanercept), 41 (control)<br />
Test for heterogeneity: NA<br />
Test for overall effect: z = 0.47 (p = 0.64)<br />
Etanercept<br />
n/N<br />
Control<br />
n/N<br />
5/103 1/50<br />
103 50<br />
44/223 41/228<br />
223 228<br />
Total (95% CI)<br />
Total events: 49 (etanercept), 42 (control)<br />
Test for heterogeneity: 2 = 0.53, df = 1 (p = 0.47), I2 326 278<br />
= 0%<br />
Test for overall effect: z = 0.68 (p = 0.50)<br />
FIGURE 20 SAE RR: etanercept licensed dose versus o<strong>the</strong>r active treatment<br />
WMD (fixed)<br />
95% CI<br />
–1 –0.5 0 0.5 1<br />
Favours etanercept Favours control<br />
RR (fixed)<br />
95% CI<br />
0.01 0.1 1 10 100<br />
Favours etanercept Favours control<br />
Weight<br />
%<br />
20.87<br />
20.87<br />
40.79<br />
38.33<br />
79.13<br />
100.00<br />
Weight<br />
%<br />
3.21<br />
3.21<br />
96.79<br />
96.79<br />
100.00<br />
WMD (fixed)<br />
95% CI<br />
–0.40 (–0.58 to –0.22)<br />
–0.40 (–0.58 to –0.22)<br />
–0.10 (–0.23 to 0.03)<br />
–0.10 (–0.23 to 0.03)<br />
–0.10 (–0.19 to –0.01)<br />
RR (fixed)<br />
95% CI<br />
2.43 (0.29 to 20.23)<br />
2.43 (0.29 to 20.23)<br />
1.10 (0.75 to 1.61)<br />
1.10 (0.75 to 1.61)<br />
1.14 (0.78 to 1.66)
Change language